ArticleThe Journal of international medical research2020
Heparin coated meta-organic framework co-delivering doxorubicin and quercetin for effective chemotherapy of lung carcinoma.
Article in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 28 citations in OpenAlex.
- Co-delivery of doxorubicin and quercetin with Angiopep-2 modified graphene oxide for targeted chemo-photothermal therapy of glioblastoma.International journal of pharmaceutics: X · 2026Article
- Evaluating the biological characteristics of targeted ZIF-8-encapsulated individual and combined drug systems for enhancedRSC advances · 2026Article
- Recent developments in quercetin nanomedicine and applications in osteoarthritis and rheumatoid arthritis therapies.Frontiers in pharmacology · 2026Review
- A pH/ROS dual-responsive system for effective chemoimmunotherapy against melanomaActa pharmaceutica Sinica. B · 2024Article
- Nanoformulations of quercetin for controlled delivery: a review of preclinical anticancer studies.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Immune-regulating camouflaged nanoplatforms: A promising strategy to improve cancer nano-immunotherapy.Bioactive materials · 2023Review
- Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Comprehensive bioinformatics analysis to identify a novel cuproptosis-related prognostic signature and its ceRNA regulatory axis and candidate traditional Chinese medicine active ingredients in lung adenocarcinoma.Frontiers in pharmacology · 2022Article
- Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.